Jupiter Wellness Signs Definitive Agreement to Merge with Next Frontier Pharmaceuticals, a Leading Drug Developer and Manufacturer of Synthetic Cannabinoid Pharmaceuticals

Owner of SYNDROS®(dronabinol), the only US-based FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid used in adults to treat: Chemotherapy Induced Nausea and Vomiting (CINV) associated in adult patients who have failed to respond adequately to conventional antiemetic treatments; and Anorexia associated with weight loss in adult patients with Acquired Immune Deficiency Syndrome (AIDS) 83,000 […]

Jupiter Wellness Announces JW-300 Clinical Trial Results

JW-300 Demonstrates Efficacy in Treatment of Developing Burns (sunburn) in a Double-Blinded Placebo Controlled Clinical Trial. JUPITER, FL / November 16, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a wellness company specializing in the clinical development of skin therapeutics announced the results of a double-blinded placebo controlled trial of JW-300 for the treatment of first degree […]

Jupiter Wellness Announces First Patient Dosing for Double-Blinded Placebo Controlled Trial of JW-300 for the Treatment of First Degree Burns

JUPITER, FL / October 19, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing a cannabinoid receptor agonist for the treatment of first degree burns, announced the enrollment and dosing of the first patient in the study. The double-blinded placebo-controlled study will enroll 50 patients with newly diagnosed first degree burns of superficial […]

Jupiter Wellness Provides Shareholder Update on Multiple Clinical & Commercial Milestones

JUPITER, FL / October 7, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today provided an update on its advancing clinical programs and commercial progress. Commercial: Photocil™ to Launch in Q1 2022 Photocil™ (“Phototherapy in a bottle”), a patented topical Over-the-Counter drug for the treatment of psoriasis and vitiligo is expected to launch in Q1 2022. Photocil […]

Jupiter Wellness Submitted a Pre-IND Meeting Request with the US FDA for its Proposed Clinical Program of JW-100 as a Treatment for Mild to Moderate Eczema

Following receipt of a Pre-Assignment number from the FDA Jupiter Wellness requests Pre-IND meeting JUPITER, FL / August 23, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a developer of enhanced skin care therapeutics and treatments focused on the endocannabinoid system today announced it has submitted a pre-IND (Investigational New Drug) meeting request with the U.S. Food […]

Jupiter Wellness Applies for IND number from the US Food and Drug Administration

Following positive results from the JW-100 investigator initiated trials for Eczema, Jupiter Wellness to commence US FDA program JUPITER, FL / August 16, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced it has requested an IND number from the US Federal Drug Administration in preparation for a pre-IND submission to review preclinical and clinical studies […]

Jupiter Wellness Closes $32.5 Million Underwritten Public Offering of Common Stock and Warrants

JUPITER, FL / July 26, 2021 / Jupiter Wellness, Inc. (the “Company”) (NASDAQ:JUPW), today announced the closing of an underwritten public offering (the “Offering”) of 11,066,258 shares (the “Company Offering Shares”) of common stock, par value $0.001 per share (“Common Stock”) to be issued by the Company, 540,884 shares (the “Selling Stockholder Shares”) of Common […]